Literature DB >> 1347865

Management of small-cell cancer of the lung.

H H Hansen1.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1347865     DOI： 10.1016/0140-6736(92)90287-d

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  15 in total

1.  MRI in detection of brain metastases at initial staging of small-cell lung cancer.

Authors:  M van de Pol; A G van Oosterhout; J T Wilmink; G P ten Velde; A Twijnstra
Journal:  Neuroradiology       Date:  1996-04       Impact factor: 2.804

2.  Efficacy and safety of prophylactic cranial irradiation in patients with small cell lung cancer.

Authors:  M van de Pol; G P ten Velde; J T Wilmink; A Volovics; A Twijnstra
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

3.  Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis.

Authors:  Yuan Zhao; Bing Wan; Tianli Zhang; Yangyang Xu; Hongbing Liu; Tangfeng Lv; Fang Zhang; Ping Zhan; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2019-12

4.  Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

Authors:  J H Schellens; J Ma; A S Planting; M E van der Burg; E van Meerten; M de Boer-Dennert; P I Schmitz; G Stoter; J Verweij
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

5.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo.

Authors:  Y Abe; Y Ohnishi; M Yoshimura; E Ota; Y Ozeki; Y Oshika; T Tokunaga; H Yamazaki; Y Ueyema; T Ogata; N Tamaoki; M Nakamura
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

6.  In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.

Authors:  P B Jensen; B Holm; M Sorensen; I J Christensen; M Sehested
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue.

Authors:  K J O'Byrne; J T Ennis; P J Freyne; L J Clancy; J S Prichard; D N Carney
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

8.  A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). I: Survival and prognostic factors. Medical Research Council Lung Cancer Working Party.

Authors:  N M Bleehen; D J Girling; D Machin; R J Stephens
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

9.  Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines.

Authors:  P B Jensen; I J Christensen; M Sehested; H H Hansen; L Vindeløv
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

10.  Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer.

Authors:  J Kreisholt; M Sorensen; P B Jensen; B S Nielsen; C B Andersen; M Sehested
Journal:  Br J Cancer       Date:  1998-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.